Joe Rogan Experience #2567 - Mariana van Zeller · Aired Oct 16, 2026
Claim summary · not a verbatim quotation
Joe describes ibogaine as one of the most effective addiction treatments and as helping traumatic brain injury.
The finding
What the evidence shows
Ibogaine has shown real promise. Small observational studies show it cuts withdrawal and cravings, and a 30-veteran Stanford study found improvements in veterans with brain injuries. But the evidence is limited. Those studies had no control groups, long-term opioid abstinence in them ranged from about 23% to 55%, and the drug carries heart risks. PolitiFact rated an earlier, stronger Rogan ibogaine claim Mostly False, so calling it "one of the most effective" treatments overstates what is known. A large randomized trial showing ibogaine beating standard addiction treatments would flip this verdict.
Read the supporting source · politifact.com ↗Quick answer & review status
Quick answer
Is it true that Joe describes ibogaine as one of the most effective addiction treatments and as helping traumatic brain injury?
It leaves out the other side. Ibogaine has shown real promise. Small observational studies show it cuts withdrawal and cravings, and a 30-veteran Stanford study found improvements in veterans with brain injuries. Joe Rogan said it (matched by voice) on Joe Rogan Experience #2567 - Mariana van Zeller, aired Oct 16, 2026, at 2:13:03. The supporting source is politifact.com, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.